In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|May 25, 2021
Almac Sciences to Invest in Continuous Flow Chemistry Equipment for New R&D Center
Author(s)BioPharm International Editors
Almac Sciences is investing in the expansion of its continuous flow chemistry equipment as an additional project to its previously announced £5-million (US$7-million) laboratory expansion.
Advertisement
Almac Sciences, a member of the Almac Group, announced on May 25, 2021 that it has invested £325,000 (US$459,000) in continuous flow chemistry equipment to further expand its most recent £5-million (US$7-million) laboratory expansion, which consisted of the construction of a two-story R&D center for flow chemistry, biocatalysis, and peptide technologies.
According to an Almac company press release, the new equipment will consist of microreactors, a photocatalysis flow rig, continuous stirred-tank reactors, a Vapourtec E series flow rig, in-house-built cryogenic rigs, microbubble and pressure technology, and spray drying, ultrafiltration/diafiltration, and liquid–liquid separation technology.
“The recent investment is critical for our strategic growth and highlights Almac Sciences’ commitment to offering our clients the best available technology solutions,” said Scott Wharry, Almac Sciences’ custom and flow chemistry manager, in the press release. “Our technology development has included the installation and commissioning of [a] high pressure hydrogenation pilot rig (with capability range up to 300 ºC and 100 Bar pressure) and, from Chemtrix, both lab- (Labtrix ) and kilo- (Protrix) scale flow rigs. These enhanced capabilities enable us to deliver superior solutions driving projects from proof-of-concept to kilo manufacture rapidly in response to our customers’ critical timelines.”
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5